Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Bapcor (BAP AU): Potential Suitors Kicking Tyres

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Bapcor, a leading autopart trader and retailer in Australia and New Zealand, announced an AUD 180 million institutional placement and AUD 30 million share purchase program this morning. In this insight, we will look at the details of the deal and provide our thoughts on the placement. </p>

Bapcor, a leading autopart trader and retailer in Australia and New Zealand, announced an AUD 180 million institutional placement and AUD 30 million share purchase program this morning. In this insight, we will look at the details of the deal and provide our thoughts on the placement. 

Bapcor Placement: Capital Raising for an Essential Service Provider

Bapcor Ltd

Bapcor Placement: Capital Raising for an Essential Service Provider